Introduction: Back to basics: Mucosal immunity and novel HIV vaccine concepts

Journal of Internal Medicine

Volumn 265, Issue 1, 2009, Pages 5-17

  Broliden, K ^a   Haase, A T ^b   Ahuja, S K ^c,d   Shearer, G M ^e   Andersson, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECALECTIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; B LYMPHOCYTE; CELL LOSS; CONFERENCE PAPER; DENDRITIC CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; INFECTION RESISTANCE; INNATE IMMUNITY; MUCOSAL IMMUNITY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIMIAN IMMUNODEFICIENCY VIRUS; TH17 CELL; VERRUCA VULGARIS; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; FEMALE; HIV-1; HUMANS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; MALE; MODELS, IMMUNOLOGICAL; MUCOUS MEMBRANE;

EID: 57449088402     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2008.02053.x     Document Type: Conference Paper

References (26)

1. Salazar-Gonzalez JF, Bailes E, Pham KT et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008 82 : 3952 70.
2. Campbell EM, Perez O, Melar M, Hope TJ. Labeling HIV-1 virions with two fluorescent proteins allows identification of virions that have productively entered the target cell. Virology 2007 360 : 286 93.
3. Cole AM, Cole AL. Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense. Am J Reprod Immunol 2008 59 : 27 34.
4. Hirbod T, Kaul R, Reichard C et al. HIV-1 neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 2008 22 : 727 35.
5. de Jong MA, de Witte L, Oudhoff MJ, Gringhuis SI, Gallay P, Geijtenbeek TB. TNF-alpha and TLR agonists increase susceptibility to HIV-1 transmission by human Langerhans cells ex vivo. J Clin Invest 2008 118 : 3440 52.
6. de Jong MAWP, Geijtenbeek TBH. Human immunodeficiency virus-1 acquisition in genital mucosa: Langerhans cells as key-players. J Intern Med 2009 265 : 18 28.
7. Martin MP, Qi Y, Gao X et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007 39 : 708 10.
8. Nag P, Kim J, Sapiega V et al. Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis 2004 190 : 1970 78.
9. Alter G, Altfeld M. NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection. J Intern Med 2009 265 : 29 42.
10. Thomas R, Yamada E, Alter G et al. Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation? J Immunol 2008 180 : 6743 50.
11. Guiducci C, Coffman RL, Barrat FJ. Signalling pathways leading to IFN-α production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. J Intern Med 2009 265 : 43 57.
12. Shacklett BL, Critchfield JW, Ferre AL, Hayes TL. Mucosal T-cell responses to HIV: responding at the front lines. J Intern Med 2009 265 : 58 66.
13. Arthos J, Cicala C, Martinelli E et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 2008 9 : 301 9.
14. Masopust D. Developing an HIV cytotoxic T-lymphocyte vaccine: issues of CD8 T-cell quantity, quality and location. J Intern Med 2009 265 : 125 37.
15. + T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6. J Intern Med 2009 265 : 67 77.
16. Cerutti A. The regulation of IgA class switching. Nat Rev Immunol. 2008 8 : 421 34.
17. Boasso A, Hardy AW, Anderson SA, Dolan MJ, Shearer GM. HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation. PLoS ONE 2008 3 : e2961.
18. Boasso A, Shearer GM, Chougnet C. Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it J Intern Med 2009 265 : 78 96.
19. Silvestri G. Immunity in natural SIV infections. J Intern Med 2009 265 : 97 109.
20. Klatt NR, Villinger F, Bostik P et al. Availability of activated CD4+ T cells dictates the level of viremia in naturally SIV-infected sooty mangabeys. J Clin Invest 2008 118 : 2039 49.
21. Piacentini L, Biasin M, Fenizia C, Clerici M. Genetic correlates of protection against HIV infection: the ally within. J Intern Med 2009 265 : 110 24.
22. Nibbs RJ, Yang J, Landau NR, Mao JH, Graham GJ. LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity. J Biol Chem 1999 274 : 17478 83.
23. Gonzalez E, Kulkarni H, Bolivar H et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005 307 : 1434 40.
24. Ball TB, Ji H, Kimani J et al. Polymorphisms in IRF-1 associated with resistance to HIV-1 infection in highly exposed uninfected Kenyan sex workers. AIDS 2007 21 : 1091 101.
25. Mascola JR, Stiegler G, VanCott TC et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000 6 : 207 10.
26. Rinaldo CR. Dendritic cell-based human immunodeficiency virus vaccine. J Intern Med 2009 265 : 138 58.